A look behind closed doors: Interaction of persistent viruses with dendritic cells

Nature Reviews Microbiology

Volumn 8, Issue 5, 2010, Pages 350-360

  Lambotin, Mélanie ^a,b   Raghuraman, Sukanya ^c   Stoll Keller, Françoise ^a,b   Baumert, Thomas F ^a,b,d   Barth, Heidi ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GENOMIC RNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE; PATTERN RECOGNITION RECEPTOR; PEGINTERFERON ALPHA; RIBAVIRIN; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL DIVISION; CELL FUNCTION; CELL HETEROGENEITY; CELL SURVIVAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; LANGERHANS CELL; MOLECULAR DYNAMICS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS CELL INTERACTION; VIRUS IMMUNITY;

ANTIGEN PRESENTATION; DENDRITIC CELLS; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE TOLERANCE; LIVER; MODELS, IMMUNOLOGICAL;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 77951094286     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro2332     Document Type: Review

References (133)

1. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
2. Wu, L. & Liu, Y. J. Development of dendritic-cell lineages. Immunity 26, 741-750 (2007).
3. Steinman, R. M. & Haemmi, H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 3 11, 17-58 (2006)
4. Liu, Y. J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275-306 (2005).
5. Colonna, M., Trinchieri, G. & Liu, Y. J. Plasmacytoid dendritic cells in immunity. Nature Immunol. 5, 1219-1226 (2004).
6. Smit, J. J. et al. The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS ONE 3, e1720 (2008).
7. - but not plasmacytoid dendritic cells. J. Exp. Med. 205, 1621-1634 (2008).
8. Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev. Immunol. 5, 215-229 (2005).
9. Guidotti, L. G. & Chisari, F. V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1, 23-61 (2006).
10. Gandhi, R. T. & Walker, B. D. Immunologic control of HIV-1. Annu. Rev. Med. 53, 149-172 (2002).
11. McMichael, A. J. & Rowland-Jones, S. L. Cellular immune responses to HIV. Nature 410, 980-987 (2001).
12. Simon, V., Ho, D. D. & Abdool Karim, Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368, 489-504 (2006).
13. Alter, M. J. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44, S6-S9 (2006).
14. Williams, R. Global challenges in liver disease. Hepatology 44, 521-526 (2006).
15. Bauer, D. & Tampe, R. Herpes viral proteins blocking the transporter associated with antigen processing TAP-from genes to function and structure. Curr. Top. Microbiol. Immunol. 269, 87-99 (2002).
16. Wu, L. & KewalRamani, V. N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nature Rev. Immunol. 6, 859-868 (2006).
17. + T lymphocytes in spleens of human immunodeficiency virus-positive patients. J. Virol. 69, 4737-4745 (1995).
18. Smed-Sörensen, A. et al. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J. Virol. 79, 8861-8869 (2005).
19. + haematopoietic progenitor cells is primarily determined by their maturation stage. Blood 93, 3866-3875 (1999).
20. Fong, L., Mengozzi, M., Abbey, N. W., Herndier, B. G. & Engleman, E. G. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J. Virol. 76, 11033-11041 (2002).
21. Goutagny, N. et al. Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J. Infect. Dis. 187, 1951-1958 (2003).
22. Rodrigue-Gervais, I. G. et al. Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients. J. Virol. 81, 5537-5546 (2007).
23. Navas, M. C. et al. Dendritic cell susceptibility to hepatitis C virus genotype 1 infection. J. Med. Virol. 67, 152-161 (2002).
24. Liang, H. et al. Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J. Virol. 83, 5693-5707 (2009).
25. Shiina, M. & Rehermann, B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 47, 385-395 (2008).
26. Ebihara, T., Shingai, M., Matsumoto, M., Wakita, T. & Seya, T. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 48, 48-58 (2008).
27. Decalf, J. et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J. Exp. Med. 204, 2423-2437 (2007).
28. Marukian, S. et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48, 1843-1850 (2008).
29. van der Molen, R. G. et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40, 738-746 (2004).
30. van der Molen, R. G., Sprengers, D., Biesta, P. J., Kusters, J. G. & Janssen, H. L. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology 44, 907-914 (2006).
31. Untergasser, A. et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 43, 539-547 (2006).
32. Lee, B., Sharron, M., Montaner, L. J., Weissman, D. & Doms, R. W. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl Acad. Sci. USA 96, 5215-5220 (1999).
33. Jensen, P. E. Recent advances in antigen processing and presentation. Nature Immunol. 8, 1041-1048 (2007).
34. Cambi, A., Koopman, M. & Figdor, C. G. How C-type lectins detect pathogens. Cell. Microbiol. 7, 481-488 (2005).
35. Moris, A. et al. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 103, 2648-2654 (2004).
36. Smith, A. L. et al. Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to the proteasome in dendritic cells. J. Exp. Med. 204, 421-430 (2007).
37. Barth, H. et al. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J. Virol. 82, 3466-3479 (2008).
38. Tang, H. & McLachlan, A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc. Natl Acad. Sci. USA 98, 1841-1846 (2001).
39. + T cells. Nature 435, 108-114 (2005).
40. Peng, G. et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110, 393-400 (2007).
41. Piguet, V. & Sattentau, Q. Dangerous liaisons at the virological synapse. J. Clin. Invest. 11 4, 605-610 (2004).
42. Geijtenbeek, T. B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597 (2000).
43. Burleigh, L. et al. Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells. J. Virol. 80, 2949-2957 (2006).
44. Turville, S. G. et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 103, 2170-2179 (2004).
45. Groot, F., van Capel, T. M., Kapsenberg, M. L., Berkhout, B. & de Jong, E. C. Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition. Blood 108, 1957-1964 (2006).
46. de Witte, L. et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nature Med. 13, 367-371 (2007).
47. Gardner, J. P. et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl Acad. Sci. USA 100, 4498-4503 (2003).
48. Pohlmann, S. et al. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77, 4070-4080 (2003).
49. Lozach, P. Y. et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278, 20358-20366 (2003).
50. Cormier, E. G. et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl Acad. Sci. USA 101, 14067-14072 (2004).
51. Ludwig, I. S. et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J. Virol. 78, 8322-8332 (2004).
52. Lai, W. K. et al. Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. Am. J. Pathol. 169, 200-208 (2006).
53. Op den Brouw, M. L. et al. Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN. J. Viral Hepat. 15, 675-683 (2008).
54. - plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98, 2574-2576 (2001).
55. + (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 98, 3016-3021 (2001).
56. Grassi, F. et al. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS 13, 759-766 (1999).
57. Chehimi, J. et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J. Immunol. 168, 4796-4801 (2002).
58. Soumelis, V. et al. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood 98, 906-912 (2001).
59. Cavaleiro, R. et al. Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease. PLoS Pathog. 5, e1000667 (2009).
60. Ulsenheimer, A. et al. Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology 41, 643-651 (2005).
61. Wertheimer, A. M., Bakke, A. & Rosen, H. R. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 40, 335-345 (2004).
62. Longman, R. S., Talal, A. H., Jacobson, I. M., Rice, C. M. & Albert, M. L. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. J. Infect. Dis. 192, 497-503 (2005).
63. Kanto, T. et al. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J. Infect. Dis. 190, 1919-1926 (2004).
64. Nattermann, J. et al. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C. Hepatology 44, 945-954 (2006).
65. Dolganiuc, A. et al. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-α and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 177, 6758-6768 (2006).
66. Xie, Q. et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect. 11, 515-523 (2009).
67. Brown, K. N., Wijewardana, V., Liu, X. & Barratt-Boyes, S. M. Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection. PLoS Pathog. 5, e1000413 (2009).
68. Meyers, J. H. et al. Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells. PLoS ONE 2, e458 (2007).
69. Kunitani, H., Shimizu, Y., Murata, H., Higuchi, K. & Watanabe, A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J. Hepatol. 36, 734-741 (2002).
70. Lai, W. K. et al. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J. Hepatol. 47, 338-347 (2007).
71. Zhang, Z. et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure. J. Hepatol. 49, 396-406 (2008).
72. Longman, R. S., Talal, A. H., Jacobson, I. M., Albert, M. L. & Rice, C. M. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 103, 1026-1029 (2004).
73. Donaghy, H., Gazzard, B., Gotch, F. & Patterson, S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 101, 4505-4511 (2003).
74. Chougnet, C. A., Margolis, D., Landay, A. L., Kessler, H. A. & Shearer, G. M. Contribution of prostaglandin E2 to the interleukin-12 defect in HIV-infected patients. AIDS 10, 1043-1045 (1996). (Pubitemid 26252638)
75. Chehimi, J. et al. Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med. 179, 1361-1366 (1994).
76. Kanto, T. et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J. Immunol. 162, 5584-5591 (1999).
77. Dolganiuc, A. et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro-and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol. 170, 5615-5624 (2003).
78. Chehimi, J. et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J. Immunol. 179, 2642-2650 (2007).
79. Conry, S. J. et al. Impaired plasmacytoid dendritic cell (PDC)-NK cell activity in viraemic human immunodeficiency virus infection attributable to impairments in both PDC and NK cell function. J. Virol. 83, 11175-11187 (2009).
80. Ahlenstiel, G. et al. Natural killer cells are polarized towards cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138, 325-335 (2010).
81. Bain, C. et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120, 512-524 (2001).
82. Dolganiuc, A., Paek, E., Kodys, K., Thomas, J. & Szabo, G. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology 135, 2119-2127 (2008).
83. Auffermann-Gretzinger, S., Keeffe, E. B. & Levy, S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97, 3171-3176 (2001).
84. Granelli-Piperno, A., Golebiowska, A., Trumpfheller, C., Siegal, F. P. & Steinman, R. M. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc. Natl Acad. Sci. USA 101, 7669-7674 (2004).
85. Piccioli, D. et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J. Hepatol. 42, 61-67 (2005).
86. Tavakoli, S. et al. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin. Exp. Immunol. 151, 61-70 (2008).
87. Kamga, I. et al. Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J. Infect. Dis. 192, 303-310 (2005).
88. Mengshol, J. A. et al. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut 58, 964-973 (2009).
89. Beignon, A. S. et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 11 5, 3265-3275 (2005).
90. Gondois-Rey, F. et al. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS ONE 4, e4319 (2009).
91. Krug, A. et al. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 103, 1433-1437 (2004).
92. Lund, J., Sato, A., Akira, S., Medzhitov, R. & Iwasaki, A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198, 513-520 (2003).
93. Xu, Y. et al. HBsAg inhibits TLR9-mediated activation and IFN-α production in plasmacytoid dendritic cells. Mol. Immunol. 46, 2640-2646 (2009).
94. Martinelli, E. et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-α secretion in plasmacytoid dendritic cells. Proc. Natl Acad. Sci. USA 104, 3396-3401 (2007).
95. Dzionek, A. et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med. 194, 1823-1834 (2001).
96. Meyer-Wentrup, F. et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood 111, 4245-4253 (2008).
97. Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762-774 (2004).
98. Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363-1372 (1999).
99. Fallarino, F. et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9, 1069-1077 (2002).
100. + T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109, 3351-3359 (2007).
101. Manches, O. et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 11 8, 3431-3439 (2008).
102. Malleret, B. et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 11 2, 4598-4608 (2008).
103. Boasso, A. et al. Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection. J. Virol. 81, 11593-11603 (2007).
104. Larrea, E. et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J. Virol. 81, 3662-3666 (2007).
105. Chen, Y. B. et al. Immunosuppressive effect of IDO on T cells in patients with chronic hepatitis B. Hepatol. Res. 39, 463-468 (2009).
106. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
107. Grossman, Z., Meier-Schellersheim, M., Paul, W. E. & Picker, L. J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nature Med. 12, 289-295 (2006).
108. Mandl, J. N. et al. Divergent TLR7 and TLR9 signalling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nature Med. 14, 1077-1087 (2008).
109. Meier, A. et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nature Med. 15, 955-959 (2009).
110. Crispe, I. N. The liver as a lymphoid organ. Annu. Rev. Immunol. 27, 147-163 (2009).
111. Qian, S. et al. Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology 19, 916-924 (1994).
112. Sumpter, T. L., Abe, M., Tokita, D. & Thomson, A. W. Dendritic cells, the liver, and transplantation. Hepatology 46, 2021-2031 (2007).
113. Royer, C. et al. A study of susceptibility of primary human Kupffer cells to hepatitis C virus. J. Hepatol. 38, 250-256 (2003).
114. Breiner, K. M., Schaller, H. & Knolle, P. A. Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms. Hepatology 34, 803-808 (2001).
115. Burgio, V. L. et al. Expression of co-stimulatory molecules by Kupffer cells in chronic hepatitis of hepatitis C virus aetiology. Hepatology 27, 1600-1606 (1998).
116. Crispe, I. N. Hepatic T cells and liver tolerance. Nature Rev. Immunol. 3, 51-62 (2003).
117. Radziewicz, H. et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81, 2545-2553 (2007).
118. Knolle, P. A. & Limmer, A. Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells. Trends Immunol. 22, 432-437 (2001).
119. Warren, A. et al. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 44, 1182-1190 (2006).
120. Dienes, H. P., Hutteroth, T., Hess, G. & Meuer, S. C. Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis B and non-A, non-B. Hepatology 7, 1317-1325 (1987).
121. Franco, A. et al. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 8, 449-454 (1988).
122. + T lymphocytes but fail to promote survival. Eur. J. Immunol. 28, 221-236 (1998).
123. Bowen, D. G. et al. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J. Clin. Invest. 11 4, 701-712 (2004)
124. Hilleman, M. R. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14560-14566 (2004).
125. Barth, H., Liang, T. J. & Baumert, T. F. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44, 527-535 (2006).
126. Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623-626 (2005).
127. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med. 11, 791-796 (2005).
128. Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102, 9294-9299 (2005).
129. Pawlotsky, J. M. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 12, 96-102 (2004).
130. Yi, M., Villanueva, R. A., Thomas, D. L., Wakita, T. & Lemon, S. M. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl Acad. Sci. USA 103, 2310-2315 (2006).
131. Gottwein, J. M. et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49, 364-377 (2009).
132. Pietschmann, T. et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl Acad. Sci. USA 103, 7408-7413 (2006).
133. Racanelli, V. & Rehermann, B. The liver as an immunological organ. Hepatology 43, S54-S62 (2006).